Delivery of apoptotic signal to rolling cancer cells: A novel biomimetic technique using immobilized TRAIL and E-Selectin

Biotechnology and Bioengineering

Volumn 102, Issue 6, 2009, Pages 1692-1702

  Rana, Kuldeepsinh ^a   Liesveld, Jane L ^b   King, Michael R ^a  

^a Cornell University   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Cancer; Cell adhesion; E selectin; Metastasis; Rolling; TRAIL

Indexed keywords

APOPTOSIS; CANCER; E-SELECTIN; METASTASIS; TRAIL;

ADHESION; BIOMIMETICS; BLOOD; CELL ADHESION; CELL DEATH; CELL MEMBRANES; PATHOLOGY; TUMORS;

ENDOTHELIAL CELLS;

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; BIOMIMETICS; BONE MARROW CELL; CANCER CELL; CANCER THERAPY; CELL ADHESION; CELL INTERACTION; CELL STRAIN HL 60; CELL VIABILITY; FLOW CYTOMETRY; FLOW RATE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; METASTASIS; MONONUCLEAR CELL; SHEAR STRESS;

APOPTOSIS; BIOMIMETIC MATERIALS; BONE MARROW CELLS; CELL ADHESION; CELL LINE, TUMOR; DATA INTERPRETATION, STATISTICAL; E-SELECTIN; FLOW CYTOMETRY; HL-60 CELLS; HUMANS; IMMOBILIZED PROTEINS; LEUKOCYTE ROLLING; LEUKOCYTES, MONONUCLEAR; NEOPLASM METASTASIS; NEOPLASMS; SURFACE PROPERTIES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 65349101638     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.22204     Document Type: Article

References (40)

1. Ashkenazi A. 2002. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2(6):420-30.
2. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, et al., 1999. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104(2):155-162.
3. Bouralexis S, Findlay DM, Atkins GJ, Labrinidis A, Hay S, Evdokiou A. 2003. Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: Resensitisation with chemotherapy. Br J Cancer 89(1):206-214.
4. Chambers AF, MacDonald IC, Schmidt EE, Koop S, Morris VL, Khokha R, Groom AC. 1995. Steps in tumor metastasis: New concepts from intravital videomicroscopy. Cancer Metastasis Rev 14(4):279-301.
5. Chambers AF, Naumov GN, Vantyghem SA, Tuck AB. 2000. Molecular biology of breast cancer metastasis. Clinical implications of experimental studies on metastatic inefficiency. Breast Cancer Res 2(6):400-407.
6. Chambers AF, Naumov GN, Varghese HJ, Nadkarni KV, MacDonald IC, Groom AC. 2001. Critical steps in hematogenous metastasis: An overview. Surg Oncol Clin N Am 10(2):243-255.
7. Charles N, Liesveld JL, King MR. 2007. Investigating the feasibility of stem cell enrichment mediated by immobilized selectins. Biotechnol Prog 23(6):1463-1472.
8. Cuello M, Ettenberg SA, Nau MM, Lipkowitz S. 2001. Synergistic induction of apoptosis by the combination of trail and chemotherapy in che- moresistant ovarian cancer cells. Gynecol Oncol 81(3):380-390.
9. Edelman MJ, Potter P, Mahaffey KG, Frink R, Leidich RB. 1996. The potential for reintroduction oftumor cells during intraoperative blood salvage: Reduction of risk with use of the RC-400 leukocyte depletion filter. Urology 47(2):179-181.
10. Fricker J. 1999. On the TRAIL to a new cancer therapy. Mol Med Today 5(9):374.
11. Fruhauf NR, Dumpich O, Kaudel CP, Kasimir-Bauer S, Oldhafer KJ. 2001. Filtration ofmalignant cells: Tumour cell depletion in an ex vivo model using a leukocyte adhesion filter. Perfusion 16 (Suppl): 51-515.
12. Gazitt Y. 1999. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 13(11):1817-1824.
13. Goetz DJ, el-Sabban ME, Hammer DA, Pauli BU. 1996. Lu-ECAM-1- mediated adhesion ofmelanoma cells to endothelium under conditions of flow. Int J Cancer 65(2):192-199.
14. Held J, Schulze-Osthoff K. 2001. Potential and caveats of TRAIL in cancer therapy. Drug Resist Updat 4(4):243-252.
15. Huntly BJ, Gilliland DG. 2005. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 5(4):311-321.
16. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC. 2000. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6(5):564-567.
17. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. 1999. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59(3):734-741.
18. Kim YJ, Borsig L, Han HL, Varki NM, Varki A. 1999. Distinct selectin ligands on colon carcinoma mucins can mediate pathological interactions among platelets, leukocytes, and endothelium. Am J Pathol 155(2):461-472.
19. Leverkus M, Neumann M, Mengling T, Rauch CT, Brocker EB, Krammer PH, Walczak H. 2000. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 60(3):553-559.
20. C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. 2007. Identification of pancreatic cancer stem cells. Cancer Res 67(3):1030-1037.
21. MacDonald IC, Groom AC, Chambers AF. 2002. Cancer spread and micrometastasis development: Quantitative approaches for in vivo models. Bioessays 24(10):885-893.
22. Mitsiades N, Poulaki V, Mitsiades C, Tsokos M. 2001. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Cancer Res 61(6):2704-2712.
23. Mizutani Y, Nakao M, Ogawa O, Yoshida O, Bonavida B, Miki T. 2001. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin. J Urol 165(1):263-270.
24. Narasipura SD, Wojciechowski JC, Charles N, Liesveld JL, King MR. 2008. P-Selectin coated microtube for enrichment of CD34+ hematopoietic stem and progenitor cells from human bone marrow. Clin Chem 54(1):77-85.
25. Ng CP, Bonavida B. 2002. A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: Two complementary signals to overcome cross-resistance. Adv Cancer Res 85:145-174.
26. Nitsch R, Bechmann I, Deisz RA, Haas D, Lehmann TN, Wendling U, Zipp F. 2000. Human brain-cell death induced by tumour-necrosis-factor- related apoptosis-inducing ligand (TRAIL). Lancet 356(9232):827-828.
27. Oikonomou E, Kothonidis K, Taoufik E, Probert E, Zografos G, Nasioulas G, Andera L, Pintzas A. 2007. Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo. Br J Cancer 97(1):73-84.
28. Orr FW, Wang HH. 2001. Tumor cell interactions with the microvascu-lature: A rate-limiting step in metastasis. Surg Oncol Clin N Am 10(2): 357-381, ix-x.
29. Orr FW, Wang HH, Lafrenie RM, Scherbarth S, Nance DM. 2000. Interactions between cancer cells and the endothelium in metastasis. J Pathol 190(3):310-329.
30. Park CH, Bergsagel DE, McCulloch EA. 1971. Mouse myeloma tumor stem cells: A primary cell culture assay. J Natl Cancer Inst 46(2):411-422.
31. Perseghin P, Vigano M, Rocco G, Della Pona C, Buscemi A, Rizzi A. 1997. Effectiveness of leukocyte filters in reducing tumor cell contamination after intraoperative blood salvage in lung cancer patients. Vox Sang 72(4):221-224.
32. Plasilova M, Zivny J, Jelinek J, Neuwirtova R, Cermak J, Necas E, Andera L, Stopka T. 2002. TRAIL (Apo2L) suppresses growth ofprimary human leukemia and myelodysplasia progenitors. Leukemia 16(1):67-73.
33. Sipkins DA, Wei X, Wu JW, Runnels JM, Cote D, Means TK, Luster AD, Scadden DT, Lin CP. 2005. In vivo imaging ofspecialized bone marrow endothelial microdomains for tumour engraftment. Nature 435(7044): 969-973.
34. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, et al., 1999. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5(2):157-163.
35. Waugh R, Evans EA. 1979. Thermoelasticity of red blood cell membrane. Biophys J 26(1):115-131.
36. Wojciechowski JC, Narasipura SD, Charles N, Mickelsen D, Rana K, Blair ML, King MR. 2008. Capture and enrichment of CD34-positive haematopoietic stem and progenitor cells from blood circulation using P-selectin in an implantable device. Br J Haematol 140(6):673-681.
37. Wojciechowski JC, Sarelius IH. 2005. Preferential binding of leukocytes to the endothelial junction region in venules in situ. Microcirculation 12(4):349-359.
38. Yu R, Mandlekar S, Ruben S, Ni J, Kong AN. 2000. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen- independent prostate cancer cells. Cancer Res 60(9):2384-2389.
39. Zamai L, Secchiero P, Pierpaoli S, Bassini A, Papa S, Alnemri ES, Guidotti L, Vitale M, Zauli G. 2000. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. Blood 95(12):3716-3724.
40. Zisman A, Ng CP, Pantuck AJ, Bonavida B, Belldegrun AS. 2001. Actino- mycin D and gemcitabine synergistically sensitize androgen-indepen-dent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis. J Immunother 24(6):459-71.